STOCK TITAN

NLS Pharmaceutics Ltd. (NLSP) Stock News, Feb-Jun 2024

NLSP NASDAQ

Ticker history: NLSP became NCEL (NewcelX Ltd.) on .

NLS Pharmaceutics Ltd. transitioned into NewcelX Ltd. after its completed merger with Kadimastem, creating a clinical-stage biotechnology company focused on cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Recurring news includes scientific advisory board updates, clinical-development themes in ALS and AstroRx, CNS pipeline additions such as the AEX-6xx series, and diabetes-program references including ITOL-102.

Company updates also cover material agreements, shareholder voting matters, capital-structure disclosures, governance changes, clinical or regulatory communications, and operating and financial results tied to the combined biotechnology business.

Rhea-AI Summary

NLS Pharmaceutics, a clinical-stage biopharmaceutical company, has announced a new patent application for dual orexin receptor agonists (DOXA), developed with Aexon Labs, targeting narcolepsy and neurodegenerative diseases like Parkinson's. These non-sulfonamide compounds are designed to reduce side effects and improve patient safety. The molecules enhance neurotransmitter release and protect neuronal health by modulating orexin receptors and inhibiting cathepsin H (CTSH), offering potential therapeutic benefits for sleep regulation and neurodegeneration. This patent represents a significant advancement in addressing unmet medical needs in both narcolepsy and neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
none
-
Rhea-AI Summary

NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
Rhea-AI Summary

NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.90%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none

FAQ

What is the current stock price of NLS Pharmaceutics (NLSP)?

NLS Pharmaceutics (NLSP) last closed at $0.7620. The company now trades as NCEL.